Company Filing History:
2 out of 26 
1 out of 1,290 
1 out of 9 Years Active: 2011-2021
Title: Nariyoshi Shinomiya: Innovator in Gout Research
Introduction: Nariyoshi Shinomiya, an accomplished inventor based in Saitama, Japan, holds four patents, demonstrating his significant contributions to medical science, particularly in the understanding and treatment of gout. His innovative approach to identifying specific molecular factors associated with uric acid-related diseases has the potential to revolutionize early treatment methods.
Latest Patents: Shinomiya's latest patents focus on inhibiting the onset of gout through the specification of various molecules. He outlines methods for evaluating diatheses of uric acid-related and inflammation-related diseases. His inventions include an evaluation kit designed for the identification and treatment of these diseases, leveraging specific proteins and cDNAs such as CNIH2-PACS1, ALDH2, MYL2-CUX2, GCKR, and others. By developing methods to detect gene variations encoding the ABCG2 protein, Shinomiya's work aims to assist in early identification of factors leading to urate transport failure and related ailments. This innovative work can significantly impact the prevention and management of gout and associated inflammation.
Career Highlights: Throughout his career, Nariyoshi Shinomiya has worked at notable research institutions such as the Van Andel Research Institute, where his expertise has contributed to advancements in understanding the genetic factors involved in gout and urate transport-related disease.
Collaborations: Shinomiya collaborated with esteemed colleagues, including George F. Vande Woude and Hirotaka Matsuo. Their combined efforts in research have helped push the boundaries of knowledge in the field of biomedicine, fostering innovation in treatments for gout and other related conditions.
Conclusion: Nariyoshi Shinomiya is a remarkable inventor whose contributions have made significant strides in the medical research field focused on gout. With his innovative patents and collaborative efforts, he continues to provide valuable insights that may enhance early treatment and prevention strategies for uric acid-related diseases, offering hope for many affected by such conditions.